Hypertension - A Companion to Braunwald's Heart Disease
By Henry R. Black, MD and William Elliott, MD, PhD
640 pages 180 ills
Trim size 8 1/2 X 10 7/8 in
Clinical hypertension is one of the most serious long-term problems associated with heart disease. This companion to Braunwald’s Heart Disease focuses in depth on this key area of cardiovascular medicine. Complete with practical clinical tools for management, it helps you manage the chronic problems of your hypertensive patients. It covers everything from epidemiology and pathophysiology through diagnosis, risk stratification, treatment, outcome studies, concomitant diseases, special populations and special situations, and future treatments.
Addresses management of all special populations with chronic hypertensive disease.
Includes Clinical Pearls for reducing complications of hypertension.
Discusses hypertension and concomitant disease.
Provides information on the practical management of hypertension and its role in complex diseases
Emphasizes prevention of hypertensive diseases.
Covers behavior management as an integral part of treatment plan for hypertensives and pre-hypertensives.
Assesses drugs and other forms of treatment.
Presents current clinical guidelines for the U.S., Canada, and Europe.
Encourages aggressive patient management to ensure minimal risk of further cardiovascular problems.
Table of Contents
Section 1: Epidemiology & Pathophysiology
1. Epidemiology 2. Genetics of Hypertension 3. Pathogenesis of Hypertension
Section 2: Diagnosis
4. Definition of Hypertension 5. Measurement of Blood 6. Home BP Measurements 7. ABPM 8. Secondary Hypertension: Renovascular Hypertension 9. Secondary Hypertension: Mineralocorticoid Excess States 10. Secondary Hypertension: Pheochromocytoma 11. Secondary Hypertension: Sleep Apnea 12. Rare Unusual Diagnoses
Section 3: Risk Stratification
13. Natural History of (Untreated) Hypertension 14. The Special Problem of (Isolated) Systolic Hypertension 15. Assessment of Target Organ Damage 16. Prediction of Global Cardiovascular Risk
Section 4: Treatment
17. Lifestyle Modifications 18. Diuretics 19. Beta-blockers 20. ACE-inhibitors and Angiotensin II Receptor Blockers 21. Calcium Antagonists 22. Alpha-Blockers 23. Other (Newer) Drugs, including centrally-acting drugs, aldosterone antagonists, vasopeptidase inhibitors, and endothelin antagonists
Section 5: Outcome Studies
24. Design of Outcomes Studies 25. Meta-analyses
Section 6: Hypertension and Concomitant Diseases
26. Ischemic Heart Disease 27. Heart Failure 28. Kidney Disease 29. Transplant Hypertension 30. Obesity 31. Peripheral Vascular Disease 32. Cerebrovascular Disease 33. Diabetes 34. Dyslipidemia
Section 7: Special Populations & Special Situations
35. Pregnancy-Related Hypertension 36. Children and Adolescents 37. Elderly 38. Blacks 39. Hispanics 40. East Asians 41. South Asians 42. Refractory Hypertension 43. Peri-operative Hypertension 44. Emergencies and Urgencies
Section 8: Hypertension Treatment in the Future
45. Hypertension Disease Management Service 46. Hypertension Genomics 47. Approval Process for Antihypertensive Drugs—US and International
Section 9: Guidelines
48. US and Canadian Guidelines 49. European Guidelines, including BHS and ESH/ESC